Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

acute kidney injury

- PMLiVE

Scientists uncover new drug target in fight against antimicrobial resistance

The discovery could lead to improved treatments for bacterial infections

- PMLiVE

Game On: Medscape Education Golfs for a Cause

Medscape Education is proud to stand alongside the National Kidney Foundation (NKF) as a sponsor of one of the nation’s most impactful charity events benefiting patients living with kidney disease,...

Medscape Education

- PMLiVE

FDA approves Apellis’ Empaveli for two rare kidney diseases

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US

- PMLiVE

Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

- PMLiVE

Otsuka shares promising phase 3 results for sibeprenlimab in rare kidney disease IgAN

The trial will continue to evaluate change in kidney function over two years

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

- PMLiVE

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

- PMLiVE

Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

There are currently no treatments that target the underlying cause of C3G or IC-MPGN

- PMLiVE

Novartis’ Fabhalta granted FDA approval for rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Alzheimer’s Research UK awards Scottish universities £100,000 for dementia research

The neurological condition affects more than 944,000 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links